A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis

Trial Profile

A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2016

At a glance

  • Drugs Sifalimumab (Primary)
  • Indications Dermatomyositis; Polymyositis; Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 20 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Jan 2014 According to the ClinicalTrials.gov record planned end date changed from 1 May 2015 to 1 Mar 2015.
    • 18 May 2012 Actual patient number is 103 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top